Characteristics of the patients
| Variable . | Value . |
|---|---|
| Age at the time of first catheter insertion, (median, 25th-75th percentile), mo | 1.0 (0.1-14.1) |
| Age at the time of first DVT, (median, 25th-75th percentile), mo | 3.6 (0.7-30.5) |
| Age at the time of first postincident DVT catheter insertion, (median, 25th-75th percentile), mo | 6.0 (0.9-34.5) |
| Sex, n (%) | |
| Male | 143 (58.4) |
| Female | 102 (41.6) |
| Underlying condition, n (%) | |
| Cardiac disease | 105 (42.9) |
| Complex* | 27 (11.0) |
| Other | |
| Cancer | 21 (8.6) |
| Inflammatory/infectious | 18 (7.3) |
| Congenital diaphragmatic hernia | 15 (6.1) |
| Prematurity | 13 (5.3) |
| Not classified | 46 (18.8) |
| Thrombophilia findings, n (%) | |
| None | 194 (79.3) |
| Minor | |
| High FVIII levels | 12 (5.0) |
| FVL heterozygous | 11 (4.5) |
| PTG heterozygous | 4 (1.6) |
| Combined† | 2 (0.8) |
| Lipoprotein (a) | 2 (0.8) |
| Major | |
| ACLA | 5 (2.0) |
| Protein S deficiency | 5 (2.0) |
| Combined‡ | 4 (1.6) |
| Protein C deficiency | 3 (1.2) |
| AT deficiency | 2 (0.8) |
| FVL homozygous | 1 (0.4) |
| Blood group, n (%) | |
| O+ | 86 (35.0) |
| O− | 12 (5.0) |
| A+ | 83 (34.0) |
| A− | 6 (2.5) |
| B+ | 43 (17.5) |
| B− | 4 (1.6) |
| AB+ | 9 (3.6) |
| AB− | 2 (0.8) |
| Variable . | Value . |
|---|---|
| Age at the time of first catheter insertion, (median, 25th-75th percentile), mo | 1.0 (0.1-14.1) |
| Age at the time of first DVT, (median, 25th-75th percentile), mo | 3.6 (0.7-30.5) |
| Age at the time of first postincident DVT catheter insertion, (median, 25th-75th percentile), mo | 6.0 (0.9-34.5) |
| Sex, n (%) | |
| Male | 143 (58.4) |
| Female | 102 (41.6) |
| Underlying condition, n (%) | |
| Cardiac disease | 105 (42.9) |
| Complex* | 27 (11.0) |
| Other | |
| Cancer | 21 (8.6) |
| Inflammatory/infectious | 18 (7.3) |
| Congenital diaphragmatic hernia | 15 (6.1) |
| Prematurity | 13 (5.3) |
| Not classified | 46 (18.8) |
| Thrombophilia findings, n (%) | |
| None | 194 (79.3) |
| Minor | |
| High FVIII levels | 12 (5.0) |
| FVL heterozygous | 11 (4.5) |
| PTG heterozygous | 4 (1.6) |
| Combined† | 2 (0.8) |
| Lipoprotein (a) | 2 (0.8) |
| Major | |
| ACLA | 5 (2.0) |
| Protein S deficiency | 5 (2.0) |
| Combined‡ | 4 (1.6) |
| Protein C deficiency | 3 (1.2) |
| AT deficiency | 2 (0.8) |
| FVL homozygous | 1 (0.4) |
| Blood group, n (%) | |
| O+ | 86 (35.0) |
| O− | 12 (5.0) |
| A+ | 83 (34.0) |
| A− | 6 (2.5) |
| B+ | 43 (17.5) |
| B− | 4 (1.6) |
| AB+ | 9 (3.6) |
| AB− | 2 (0.8) |
ACLA, anticardiolipin antibody; AT, antithrombin; FVL, factor V Leiden; PTG, prothrombin gene mutation.
Complex: diseases leading to organ transplant, genetic disorders with complications, diseases with neurologic complications.
High FVIII and heterozygous FVL (n = 2).
Protein C and protein S deficiency (n = 1)/ACLA and heterozygous FVL (n = 1)/AT and protein S deficiency (n = 1)/AT deficiency and heterozygous FVL (n = 1).